

## ASX ANNOUNCEMENT

### Charlie Shahin AO becomes largest shareholder of Vitura

30 JULY 2025

**Melbourne, Australia** – Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**), a leading digital health platform business for traditional and emerging therapies in Australia, is pleased to announce that AFO Investments Pty Ltd, as Trustee for the AFO Investment Trust (**AFO**), an entity associated with South Australian based high-net-worth investor Professor Khalil (Charlie) Shahin AO, has recently become the largest shareholder in the Company.

As disclosed in the *Form 604 Notice of change of interests of substantial holder* that was released to the ASX today, AFO now holds a total of 114,464,236 shares in Vitura, representing 17.29% of the total shares on issue, making AFO the largest single shareholder in Vitura. As a result of the change, Elizabeth Sarah Jansen, as Trustee for the Stanford Investment Trust, now holds a total of 85,621,544 shares in Vitura, representing 12.93% of the total shares on issue

Commenting on his purchase of further shares in Vitura, Professor Shahin said:

*"I am very pleased to have increased my stake in Vitura Health and to become the Company's largest shareholder. I can see considerable potential for Vitura and remain committed to working with the Company and its team to achieve further growth and deliver long term value for all shareholders".*

Commenting on the purchase by Professor Shahin, Independent Chair, Robert Iervasi said:

*"On behalf of the Board, we are pleased to see Charlie Shahin's continued commitment to Vitura and we welcome his support for the Company and look forward to working more closely with him in the future to deliver of Vitura's long term strategy."*

\*\* ENDS \*\*

## About Vitura Health Limited (ASX: VIT)

[www.vitura.com.au](http://www.vitura.com.au)

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes almost 650 therapeutic product and device SKUs within Australia from roughly 65 international and domestic brands.

- [www.canview.com.au](http://www.canview.com.au)

Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- [www.doctorsondemand.com.au](http://www.doctorsondemand.com.au)

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.

- [www.cortexa.com.au](http://www.cortexa.com.au)

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- [www.candor.com.au](http://www.candor.com.au)

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- [www.releaf.com.au](http://www.releaf.com.au)

The Company owns a 50% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- [www.cdaclinics.com.au](http://www.cdaclinics.com.au)

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- [www.cannadoc.com.au](http://www.cannadoc.com.au)

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

### **Authorised by**

Robert Iervasi, Chair and Non-Executive Director

### **Contact**

#### **Vitura Health Limited**

Robert Iervasi  
Chair  
1300 799 491  
[info@vitura.com.au](mailto:info@vitura.com.au)

#### **Media enquiries**

Dieter Lehmann  
Nominis Communications  
+61 427 672 995  
[dieter@nominis.me](mailto:dieter@nominis.me)

### **Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.